Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification
Reexamination Certificate
2011-02-01
2011-02-01
Prouty, Rebecca E. (Department: 1652)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
C435S455000, C435S471000, C435S069100, C536S024100
Reexamination Certificate
active
07879609
ABSTRACT:
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5416017 (1995-05-01), Burton et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5907083 (1999-05-01), Robert et al.
patent: 5919656 (1999-07-01), Harrington et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6054575 (2000-04-01), Villeponteau et al.
patent: 6083717 (2000-07-01), Madzak et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6175060 (2001-01-01), Lefebvre et al.
patent: 6228643 (2001-05-01), Greenland et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 8261556 (2001-07-01), Weinrich et al.
patent: 6271437 (2001-08-01), Jessen et al.
patent: 6274790 (2001-08-01), Kunst et al.
patent: 6281409 (2001-08-01), Woodhead et al.
patent: 6300095 (2001-10-01), Barredo Fuente et al.
patent: 6306656 (2001-10-01), Liu et al.
patent: 6309867 (2001-10-01), Cech et al.
patent: 6331527 (2001-12-01), Parmacek et al.
patent: 6337200 (2002-01-01), Morin et al.
patent: 6444650 (2002-09-01), Cech et al.
patent: 6475789 (2002-11-01), Cech et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6617110 (2003-09-01), Cech et al.
patent: 6627190 (2003-09-01), Wold
patent: 6627619 (2003-09-01), Cech et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6686159 (2004-02-01), Andrews et al.
patent: 6767719 (2004-07-01), Morin et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 6808880 (2004-10-01), Cech et al.
patent: 6916642 (2005-07-01), Kilian et al.
patent: 6921664 (2005-07-01), Cech et al.
patent: 6927285 (2005-08-01), Cech et al.
patent: 7005262 (2006-02-01), Cech et al.
patent: 7056513 (2006-06-01), Cech et al.
patent: 7091021 (2006-08-01), Morin
patent: 7195911 (2007-03-01), Cech et al.
patent: 7199234 (2007-04-01), Morin et al.
patent: 7211435 (2007-05-01), Andrews et al.
patent: 7226744 (2007-06-01), Andrews et al.
patent: 7262288 (2007-08-01), Cech et al.
patent: 7279328 (2007-10-01), Andrews et al.
patent: 7285639 (2007-10-01), Cech et al.
patent: 7297488 (2007-11-01), Cech et al.
patent: 7351697 (2008-04-01), Kupper et al.
patent: 7378244 (2008-05-01), Morin et al.
patent: 7413864 (2008-08-01), Cech et al.
patent: 7473418 (2009-01-01), Yu et al.
patent: 7517971 (2009-04-01), Cech et al.
patent: 7560437 (2009-07-01), Cech et al.
patent: 7585622 (2009-09-01), Cech et al.
patent: 2003/0050264 (2003-03-01), Andrews et al.
patent: 2003/0096732 (2003-05-01), Andrews et al.
patent: 2003/0099616 (2003-05-01), Karpf et al.
patent: 2003/0104420 (2003-06-01), Andrews
patent: 2003/0113760 (2003-06-01), Andrews et al.
patent: 2003/0171326 (2003-09-01), Andrews et al.
patent: 2003/0211965 (2003-11-01), Andrews et al.
patent: 2004/0072787 (2004-04-01), Morin et al.
patent: 2004/0242529 (2004-12-01), Cech et al.
patent: 2004/0253701 (2004-12-01), Morin et al.
patent: 2005/0013825 (2005-01-01), Cech et al.
patent: 2005/0176629 (2005-08-01), Andrews et al.
patent: 2005/0214923 (2005-09-01), Yu et al.
patent: 2005/0250186 (2005-11-01), Andrews et al.
patent: 2006/0029962 (2006-02-01), Andrews et al.
patent: 2006/0040307 (2006-02-01), Cech et al.
patent: 2006/0199171 (2006-09-01), Andrews et al.
patent: 2006/0275267 (2006-12-01), Morin
patent: 2006/0281106 (2006-12-01), Andrews et al.
patent: 2007/0077226 (2007-04-01), Liu et al.
patent: 2007/0122401 (2007-05-01), Andrews et al.
patent: 2007/0238639 (2007-10-01), Andrews et al.
patent: 2008/0058277 (2008-03-01), Andrews et al.
patent: 2008/0166711 (2008-07-01), Andrews et al.
patent: 2008/0176223 (2008-07-01), Andrews et al.
patent: 2008/0279871 (2008-11-01), Cech et al.
patent: 2009/0099125 (2009-04-01), Yu et al.
patent: 2009/0111157 (2009-04-01), Morin
patent: 2362367 (2000-08-01), None
patent: 1 859 804 (2007-11-01), None
patent: 2317891 (1998-04-01), None
patent: 2321642 (2000-09-01), None
patent: 09-154575 (1997-06-01), None
patent: WO-84/03564 (1984-09-01), None
patent: WO 95/13382 (1995-05-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO-96/12811 (1996-05-01), None
patent: WO-96/19580 (1996-06-01), None
patent: WO 96/40868 (1996-12-01), None
patent: WO-98/01542 (1998-01-01), None
patent: WO-98/01543 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/08938 (1998-03-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO-98/45450 (1998-10-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 99/01560 (1999-01-01), None
patent: WO 99/33998 (1999-07-01), None
patent: WO 99/38964 (1999-08-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO-01/23004 (2001-04-01), None
patent: WO 02/16657 (2002-02-01), None
patent: WO 02/16658 (2002-02-01), None
patent: WO 02/070668 (2002-09-01), None
patent: WO 02/072787 (2002-09-01), None
patent: WO 02/090570 (2002-11-01), None
patent: WO 02/090571 (2002-11-01), None
patent: WO 02/101010 (2002-12-01), None
patent: WO 03/000916 (2003-01-01), None
patent: WO 03/016474 (2003-02-01), None
Autexier et al., “Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA,”EMBO J. 15:5928-35 (1996).
Berenstein, M., et al., “Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells,”Cancer Gene Therapy6(4):358-66 (1999).
Bi, W. et al., “An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice,”Cancer Gene Therapy4(4):246-52 (1997).
Brand, K. et al., “Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach,”Gene Therapy5:1363-71 (1998).
Cong, Y. et al., “The Human Telomerase Catalytic Subunit hTERT: Organization of the Gene and Characterization of the Promoter,”Human Molecular Genetics8(1):137-42 (1999).
Counter et al., “The catalytic subunit of yeast telomerase.”Proc. Nat'l Acad Sc!. U.S.A.94:9202-9207 (1997).
Devereaux, T. et al., “DNA Methylation Analysis of the Promoter Region of the Human Telomerase Reverse Transcriptase (hTERT) Gene,”Cancer Res.59:6087-90 (1999).
Eishami, A. et al., “The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo,”Cancer Gene Therapy4(4):213-21 (1997).
Feng et al., “The RNA Component of Human Telomerase,”Science269:1236 (1995).
Genbank AA281296, EST (Apr. 2, 1997).
Geron Corporation Press Release. Geron Corporation and Genetic Therapy, Inc. partner to develop cancer therapy (Jan. 7, 2002).
Gu et al., “Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the
Andrews William H.
Morin Gregg B.
Geron Corporation
Mooi Leslie A.
Prouty Rebecca E.
LandOfFree
Regulatory segments of the human gene for telomerase reverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulatory segments of the human gene for telomerase reverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulatory segments of the human gene for telomerase reverse... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619973